MEK MUTATION
Clinical trials for MEK MUTATION explained in plain language.
Never miss a new study
Get alerted when new MEK MUTATION trials appear
Sign up with your email to follow new studies for MEK MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Last-Resort drug made available for patients with tough cancers
Disease control AVAILABLEThis program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…
Matched conditions: MEK MUTATION
Sponsor: xCures • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New pill targets hard-to-treat cancers with MAPK mutations
Disease control Recruiting nowThis early-stage study tests an experimental oral drug, NST-628, in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. About 230 participants w…
Matched conditions: MEK MUTATION
Phase: PHASE1 • Sponsor: Nested Therapeutics, Inc • Aim: Disease control
Last updated May 11, 2026 20:46 UTC